Pharvaris (PHVS) Enterprise Value (2019 - 2026)
Pharvaris posted quarterly Enterprise Value of -$341.5 million for Q1 2026, down 15.64% year-on-year from -$404.8 million in Q1 2025, and down 0.58% on a QoQ basis from -$339.5 million in Q4 2025.
Pharvaris (PHVS) has 8 years of Enterprise Value data on file, last reported at -$341.5 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 15.64% year-over-year to -$341.5 million; the trailing twelve-month figure through Mar 2026 stood at -$341.5 million (down 15.64% YoY), and the FY2025 full-year result was -$329.5 million, down 8.46% from the prior year.
- Enterprise Value for Q1 2026 stood at -$341.5 million, down from -$339.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$165.1 million in Q4 2022 and bottomed at -$420.9 million in Q4 2023.
- The 5-year median for Enterprise Value is -$319.8 million (2024), against an average of -$310.4 million.
- The widest annual swing landed in 2022, when Enterprise Value soared 31.06%; it then plunged 154.94% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$165.1 million in 2022, then slumped by 154.94% to -$420.9 million in 2023, then increased by 28.73% to -$300.0 million in 2024, then decreased by 13.18% to -$339.5 million in 2025, then retreated by 0.58% to -$341.5 million in 2026.
- The last three Enterprise Value figures came in at -$341.5 million (Q1 2026), -$339.5 million (Q4 2025), and -$295.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | -341.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -341.48 Mn |
| Dec 31, 2025 | -339.53 Mn |
| Mar 31, 2025 | -295.29 Mn |
| Dec 31, 2024 | -299.98 Mn |
| Dec 31, 2023 | -420.94 Mn |
| Dec 31, 2022 | -165.11 Mn |
| Dec 31, 2021 | -239.49 Mn |
| Dec 31, 2020 | -117.59 Mn |
| Dec 31, 2019 | -22.50 Mn |